Truist Securities has significantly lowered its price target for Humana to $200 from $285, while retaining a “Hold” rating on the stock. This adjustment reflects a broader trend among analysts, with several other firms also reducing their price targets for Humana around the same period, citing various headwinds. Humana Inc. is a leading health insurance provider with a strong focus on government-sponsored plans and supplementary medical services.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Truist Securities Adjusts Humana Price Target to $200 From $285, Maintains Hold Rating
Truist Securities has significantly lowered its price target for Humana to $200 from $285, while retaining a “Hold” rating on the stock. This adjustment reflects a broader trend among analysts, with several other firms also reducing their price targets for Humana around the same period, citing various headwinds. Humana Inc. is a leading health insurance provider with a strong focus on government-sponsored plans and supplementary medical services.